Bio-Rad Laboratories, Inc. BIO.B Debt and Equity Securities, Unrealized Gain (Loss)
Debt and Equity Securities, Unrealized Gain (Loss) at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss.
The official record: Bio-Rad Laboratories, Inc.’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss)?
- Bio-Rad Laboratories, Inc. (BIO.B) reported debt and equity securities, unrealized gain (loss) of $225.1M in Q4 2025.
- How has Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss) changed year-over-year?
- Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss) increased by 133.9% year-over-year, from -$664.2M to $225.1M.
- What is the long-term trend for Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss)?
- Over 3 years (2022 to 2025), Bio-Rad Laboratories, Inc.'s debt and equity securities, unrealized gain (loss) has grown at a -44.2% compound annual growth rate (CAGR), from -$5.19B to $900.4M.
- What does debt and equity securities, unrealized gain (loss) mean?
- Changes in the value of investment holdings that have not yet been sold.
- How do you interpret debt and equity securities, unrealized gain (loss)?
- Large gains or losses indicate high exposure to market volatility in the company's investment portfolio.
- How does debt and equity securities, unrealized gain (loss) compare across companies?
- Common for companies with significant strategic investments or venture-like holdings in their sector.